Magyar
Toggle navigation
Tudóstér
Magyar
Tudóstér
Keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Böngészés
Saját polc tartalma
(
0
)
Korábbi keresések
CCL parancs
CCL
Összesen 9 találat.
#/oldal:
12
36
60
120
Rövid
Hosszú
MARC
Részletezés:
Rendezés:
Szerző növekvő
Szerző csökkenő
Cím növekvő
Cím csökkenő
Dátum növekvő
Dátum csökkenő
1.
001-es BibID:
BIBFORM120111
035-os BibID:
(WoS)000972023600001 (Scopus)85169503780
Első szerző:
Ali, Sasha Saadia
Cím:
Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies : results from the COVAD study / Ali Sasha Saadia, R. Naveen, Sen Parikshit, Day Jessica, Joshi Mrudula, Nune Arvind, Nikiphorou Elena, Saha Sreoshy, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Velikova Tsvetelina, Milchert Marcin, Jagtap Kshitij, Parodis Ioannis, Edgar Gracia-Ramos Abraham, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Chen Yi Ming, Makol Ashima, Agarwal Vishwesh, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Zamora Tehozol Erick Adrian, Rojas Serrano Jorge, La Torre Ignacio García-De, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Goo Phonpen Akawatcharangura, Shumnalieva Russka, Hoff Leonardo Santos, El Kibbi Lina, Halabi Hussein, Vaidya Binit, Shaharir Syahrul Sazliyana, Hasan A. T. M. Tanveer, Dey Dzifa, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo Vinicio, Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Distler Oliver, Saavedra Miguel A., Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika, COVAD Study Group
Dátum:
2023
ISSN:
1462-0324 1462-0332
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
levél
folyóiratcikk
Megjelenés:
Rheumatology. - 62 : 9 (2023), p. e263-e268. -
További szerzők:
R., Naveen
Sen, Parikshit
Day, Jessica
Joshi, Mrudula
Nune, Arvind
Nikiphorou, Elena (reumatológus)
Saha, Sreoshy
Tan, Ai Lyn
Shinjo, Samuel Katsuyuki
Ziade, Nelly
Velikova, Tsvetelina
Milchert, Marcin
Jagtap, Kshitij
Parodis, Ioannis
Gracia-Ramos, Abraham Edgar
Cavagna, Lorenzo
Kuwana, Masataka
Knitza, Johannes
Chen, Yi Ming
Makol, Ashima
Agarwal, Vishwesh
Patel, Aarat
Pauling, John D.
Wincup, Chris
Barman, Bhupen
Zamora Tehozol, Erick Adrian
Rojas Serrano, Jorge
La Torre, Ignacio García-De
Colunga-Pedraza, Iris J.
Merayo-Chalico, Javier
Chibuzo, Okwara Celestine
Katchamart, Wanruchada
Akawatcharangura Goo, Phonpen
Shumnalieva, Russka
Hoff, Leonardo Santos
El Kibbi, Lina
Halabi, Hussein
Vaidya, Binit
Shaharir, Syahrul Sazliyana
Hasan, A. T. M. Tanveer
Dey, Dzifa
Gutiérrez, Carlos-Enrique Toro
Caballero-Uribe, Carlo Vinicio
Lilleker, James B.
Salim, Babur
Gheita, Tamer A.
Chatterjee, Tulika
Distler, Oliver
Saavedra, Miguel A.
Chinoy, Hector
Agarwal, Vikas
Aggarwal, Rohit
Gupta, Latika
Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Nagy-Vincze Melinda (1985-) (orvos)
COVAD Study Group
Internet cím:
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
2.
001-es BibID:
BIBFORM117878
035-os BibID:
(WOS)001051657500001
Első szerző:
Andreoli, Laura
Cím:
COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases : results from the COVAD study / Andreoli Laura, Lini Daniele, Schreiber Karen, Parodis Ioannis, Sen Parikshit, Ravichandran Naveen, Day Jessica, Joshi Mrudula, Jagtap Kshitij, Nune Arvind, Nikiphorou Elena, Agarwal Vishwesh, Saha Sreoshy, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Velikova Tsvetelina, Milchert Marcin, Gracia-Ramos, Abraham Edgar, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Makol Ashima, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Zamora Tehozol Erick Adrian, Serrano Jorge Rojas, De La Torre Ignacio García, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Akarawatcharangura Goo Phonpen, Shumnalieva Russka, Chen Yi-Ming, Hoff Leonardo Santos, El Kibbi Lina, Halabi Hussein, Vaidya Binit, Shaharir Syahrul Sazliyana, Hasan A. T. M. Tanveer, Dey Dzifa, Toro Gutiérrez Carlos Enrique, Caballero-Uribe Carlo V., Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Saavedra Miguel A., Distler Oliver, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika, COVAD Study Group
Dátum:
2023
ISSN:
1462-0324 1462-0332
Megjegyzések:
Objectives: We investigated COVID-19 vaccine safety in pregnant and breastfeeding women with autoimmune diseases (AID) in the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Methods: Delayed-onset (>7 days) vaccine-related adverse events (AE), disease flares (DF), and AID-related treatment modifications were analyzed upon diagnosis of AID versus healthy controls (HC) and the pregnancy/breastfeeding status at the time of at least one dose of vaccine. Results: Among the 9201 participants to the self-administered online survey, 6787 (73.8%) were women. Forty pregnant and 52 breastfeeding patients with AID were identified, of whom the majority had received at least one dose of COVID-19 vaccine (100% and 96.2%, respectively). AE were reported significantly more frequently in pregnant than in non-pregnant patients (overall AE 45% vs 26%, p= 0.01; minor AE 40% vs 25.9%, p= 0.03; major AE 17.5% vs 4.6%, p< 0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC with respect to AE. Post-vaccination DF were reported by 17.5% of pregnant and 20% of breastfeeding patients, and by 18.3% of age- and disease-matched non-pregnant and non-breastfeeding patients (n = 262). All pregnant/breastfeeding patients who experienced a DF were managed with glucocorticoids; 28.6% and 20% of them required initiation or change in immunosuppressants, respectively. Conclusion: This study provides reassuring insights into the safety of COVID-19 vaccines administered to women with AID during the gestational and post-partum periods, helping overcome hesitant attitudes, as the benefits for the mother and the fetus by passive immunization appear to outweigh potential risks.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19 vaccination
adverse events
autoimmune diseases
breastfeeding
disease flare
pregnancy
treatment
Megjelenés:
Rheumatology. - [Epub ahead of print] (2023). -
További szerzők:
Lini, Daniele
Schreiber, Karen
Parodis, Ioannis
Sen, Parikshit
Ravichandran, Naveen
Day, Jessica
Joshi, Mrudula
Jagtap, Kshitij
Nune, Arvind
Nikiphorou, Elena (reumatológus)
Agarwal, Vishwesh
Saha, Sreoshy
Tan, Ai Lyn
Shinjo, Samuel Katsuyuki
Ziade, Nelly
Velikova, Tsvetelina
Milchert, Marcin
Gracia-Ramos, Abraham Edgar
Cavagna, Lorenzo
Kuwana, Masataka
Knitza, Johannes
Makol, Ashima
Patel, Aarat
Pauling, John D.
Wincup, Chris
Barman, Bhupen
Zamora Tehozol, Erick Adrian
Serrano, Jorge Rojas
De La Torre, Ignacio García
Colunga-Pedraza, Iris J.
Merayo-Chalico, Javier
Chibuzo, Okwara Celestine
Katchamart, Wanruchada
Akawatcharangura Goo, Phonpen
Shumnalieva, Russka
Chen, Yi-Ming
Hoff, Leonardo Santos
El Kibbi, Lina
Halabi, Hussein
Vaidya, Binit
Shaharir, Syahrul Sazliyana
Hasan, A. T. M. Tanveer
Dey, Dzifa
Toro Gutiérrez, Carlos Enrique
Caballero-Uribe, Carlo Vinicio
Lilleker, James B.
Salim, Babur
Gheita, Tamer A.
Chatterjee, Tulika
Saavedra, Miguel A.
Distler, Oliver
Chinoy, Hector
Agarwal, Vikas
Aggarwal, Rohit
Gupta, Latika
Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Nagy-Vincze Melinda (1985-) (orvos)
COVAD Study Group
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
3.
001-es BibID:
BIBFORM105682
035-os BibID:
(Scopus)85160969875 (WoS)000892566100001
Első szerző:
Andreoli, Laura
Cím:
COVID-19 vaccine safety during the antenatal period in women with idiopathic inflammatory myopathies / Andreoli Laura, Sen Parikshit, Lini Daniele, Vincze Melinda Nagy, Schreiber Karen, Agarwal Vikas, Aggarwal Rohit, Gupta Latika, COVAD Study Group
Dátum:
2023
ISSN:
1462-0324 1462-0332
Megjegyzések:
Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
levél
folyóiratcikk
Autoimmune diseases
COVID-19
Long-term adverse effects
Registries
Vaccination
Megjelenés:
Rheumatology. - 62 : 6 (2023), p. e175-e179. -
További szerzők:
Sen, Parikshit
Lini, Daniele
Nagy-Vincze Melinda (1985-) (orvos)
Schreiber, Karen
Agarwal, Vikas
Aggarwal, Rohit
Gupta, Latika
Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
COVAD Study Group
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
4.
001-es BibID:
BIBFORM117879
035-os BibID:
(scopus)85162972096 (wos)001014747300001
Első szerző:
Doskaliuk, Bohdana
Cím:
Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies : results from the COVAD study / Doskaliuk Bohdana, Ravichandran Naveen, Sen Parikshit, Day Jessica, Joshi Mrudula, Nune Arvind, Nikiphorou Elena, Saha Sreoshy, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Velikova Tsvetelina, Milchert Marcin, Jagtap Kshitij, Parodis Ioannis, Gracia-Ramos Abraham Edgar, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Chen Yi Ming, Makol Ashima, Agarwal Vishwesh, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Tehozol Erick Adrian Zamora, Serrano Jorge Rojas, La Torre Ignacio García-De, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Goo Phonpen Akarawatcharangura, Shumnalieva Russka, Hoff Leonardo Santos, Kibbi Lina El, Halabi Hussein, Vaidya Binit, Shaharir Syahrul Sazliyana, Hasan A. T. M. Tanveer, Dey Dzifa, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo V., Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Distler Oliver, Saavedra Miguel A., COVAD study group, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika
Dátum:
2023
ISSN:
0172-8172 1437-160X
Megjegyzések:
Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute to vaccine hesitancy. We studied delayed-onset vaccine adverse events (AEs) in patients with IIMs, other systemic autoimmune and inflammatory disorders (SAIDs), and healthy controls (HCs), using data from the second COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. A validated self-reporting e-survey was circulated by the COVAD study group (157 collaborators, 106 countries) from Feb-June 2022. We collected data on demographics, comorbidities, IIM/SAID details, COVID-19 history, and vaccination details. Delayed-onset (> 7 day) AEs were analyzed using regression models. A total of 15165 respondents undertook the survey, of whom 8759 responses from vaccinated individuals [median age 46 (35-58) years, 74.4% females, 45.4% Caucasians] were analyzed. Of these, 1390 (15.9%) had IIMs, 50.6% other SAIDs, and 33.5% HCs. Among IIMs, 16.3% and 10.2% patients reported minor and major AEs, respectively, and 0.72% (n = 10) required hospitalization. Notably patients with IIMs experienced fewer minor AEs than other SAIDs, though rashes were expectedly more than HCs [OR 4.0; 95% CI 2.2-7.0, p < 0.001]. IIM patients with active disease, overlap myositis, autoimmune comorbidities, and ChadOx1 nCOV-19 (Oxford/AstraZeneca) recipients reported AEs more often, while those with inclusion body myositis, and BNT162b2 (Pfizer) recipients reported fewer AEs. Vaccination is reassuringly safe in individuals with IIMs, with AEs, hospitalizations comparable to SAIDs, and largely limited to those with autoimmune multimorbidity and active disease. These observations may inform guidelines to identify high-risk patients warranting close monitoring in the post-vaccination period.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Adverse event
Autoimmunity
COVID-19
Myositis
Surveys and questionnaires
Vaccination
Megjelenés:
Rheumatology International. - 43 : 9 (2023), p. 1651-1664. -
További szerzők:
Ravichandran, Naveen
Sen, Parikshit
Day, Jessica
Joshi, Mrudula
Nune, Arvind
Nikiphorou, Elena (reumatológus)
Saha, Sreoshy
Tan, Ai Lyn
Shinjo, Samuel Katsuyuki
Ziade, Nelly
Velikova, Tsvetelina
Milchert, Marcin
Jagtap, Kshitij
Parodis, Ioannis
Gracia-Ramos, Abraham Edgar
Cavagna, Lorenzo
Kuwana, Masataka
Knitza, Johannes
Chen, Yi Ming
Makol, Ashima
Agarwal, Vishwesh
Patel, Aarat
Pauling, John D.
Wincup, Chris
Barman, Bhupen
Tehozol, Erick Adrian Zamora
Serrano, Jorge Rojas
La Torre, Ignacio García-De
Colunga-Pedraza, Iris J.
Merayo-Chalico, Javier
Chibuzo, Okwara Celestine
Katchamart, Wanruchada
Akawatcharangura Goo, Phonpen
Shumnalieva, Russka
Hoff, Leonardo Santos
Kibbi, Lina El
Halabi, Hussein
Vaidya, Binit
Shaharir, Syahrul Sazliyana
Hasan, A. T. M. Tanveer
Dey, Dzifa
Gutiérrez, Carlos-Enrique Toro
Caballero-Uribe, Carlo Vinicio
Lilleker, James B.
Salim, Babur
Gheita, Tamer A.
Chatterjee, Tulika
Distler, Oliver
Saavedra, Miguel A.
Chinoy, Hector
Agarwal, Vikas
Aggarwal, Rohit
Gupta, Latika
Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Nagy-Vincze Melinda (1985-) (orvos)
COVAD Study Group
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
5.
001-es BibID:
BIBFORM105749
035-os BibID:
(scopus)85139571711 (wos)000840395200001
Első szerző:
Fazal, Zoha Zahid
Cím:
COVAD survey 2 long-term outcomes : unmet need and protocol / Fazal Zoha Zahid, Sen Parikshit, Joshi Mrudula, Ravichandran Naveen, Lilleker James B., Agarwal Vishwesh, Kardes Sinan, Kim Minchul, Day Jessica, Makol Ashima, Milchert Marcin, Gheita Tamer, Salim Babur, Velikova Tsvetelina, Gracia-Ramos Abraham Edgar, Parodis Ioannis, Nikiphorou Elena, Tan Ai Lyn, Chatterjee Tulika, Cavagna Lorenzo, Saavedra Miguel A., Shinjo Samuel Katsuyuki, Ziade Nelly, Selva-O'Callaghan Albert, Nune Arvind, Knitza Johannes, Kuwana Masataka, Gutiérrez Carlos-Enrique Toro, Caballero-Uribe Carlo Vinicio, Dey Dzifa, Distler Oliver, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika, COVAD Study Group
Dátum:
2022
ISSN:
0172-8172 1437-160X
Megjegyzések:
Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Autoimmune diseases
COVID-19
Long-term adverse effects
Registries
Vaccination
Megjelenés:
Rheumatology International. - 42 : 12 (2022), p. 2151-2158. -
További szerzők:
Sen, Parikshit
Joshi, Mrudula
Ravichandran, Naveen
Lilleker, James B.
Agarwal, Vishwesh
Kardes, Sinan
Kim, Minchul
Day, Jessica
Makol, Ashima
Milchert, Marcin
Gheita, Tamer A.
Salim, Babur
Velikova, Tsvetelina
Gracia-Ramos, Abraham Edgar
Parodis, Ioannis
Nikiphorou, Elena (reumatológus)
Tan, Ai Lyn
Chatterjee, Tulika
Cavagna, Lorenzo
Saavedra, Miguel A.
Shinjo, Samuel Katsuyuki
Ziade, Nelly
Selva-O'Callaghan, Albert
Nune, Arvind
Knitza, Johannes
Kuwana, Masataka
Gutiérrez, Carlos-Enrique Toro
Caballero-Uribe, Carlo Vinicio
Dey, Dzifa
Distler, Oliver
Chinoy, Hector
Agarwal, Vikas
Aggarwal, Rohit
Gupta, Latika
Nagy-Vincze Melinda (1985-) (orvos)
Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
COVAD Study Group
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
6.
001-es BibID:
BIBFORM120112
035-os BibID:
(WoS)000992238900001 (Scopus)85178648976
Első szerző:
Jagtap, Kshitij
Cím:
Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period : a cross-sequential study based on COVAD surveys / Jagtap Kshitij, Naveen R., Day Jessica, Sen Parikshit, Vaidya Binit, Nune Arvind, Nikiphorou Elena, Tan Ai Lyn, Agarwal Vishwesh, Saha Sreoshy, Shinjo Samuel Katsuyuki, Ziade Nelly, Joshi Mrudula, Velikova Tsvetelina, Milchert Marcin, Parodis Ioannis, Edgar Gracia-Ramos Abraham, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Makol Ashima, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Zamora Tehozol Erick Adrian, Rojas Serrano Jorge, García-De La Torre Ignacio, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Goo Phonpen Akawatcharangura, Shumnalieva Russka, Chen Yi-Ming, Hoff Leonardo Santos, El Kibbi Lina, Halabi Hussein, Sazliyana Shaharir Syahrul, Hasan A. T. M. Tanveer, Dey Dzifa, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo Vinicio, Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Saavedra Miguel A., Distler Oliver, COVAD Study Group, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika
Dátum:
2023
ISSN:
1462-0324 1462-0332
Megjegyzések:
Objective: Flares of autoimmune rheumatic diseases (AIRDs) following COVID-19 vaccination are a particular concern in vaccine-hesitant individuals. Therefore, we investigated the incidence, predictors and patterns of flares following vaccination in individuals living with AIRDs, using global COVID-19 Vaccination in Autoimmune Diseases (COVAD) surveys. Methods: The COVAD surveys were used to extract data on flare demographics, comorbidities, COVID-19 history, and vaccination details for patients with AIRDs. Flares following vaccination were identified as patient-reported (a), increased immunosuppression (b), clinical exacerbations (c) and worsening of PROMIS scores (d). We studied flare characteristics and used regression models to differentiate flares among various AIRDs. Results: Of 15 165 total responses, the incidence of flares in 3453 patients with AIRDs was 11.3%, 14.8%, 9.5% and 26.7% by definitions a-d, respectively. There was moderate agreement between patient-reported and immunosuppression-defined flares (K = 0.403, P = 0.022). Arthritis (61.6%) and fatigue (58.8%) were the most commonly reported symptoms. Self-reported flares were associated with higher comorbidities (P = 0.013), mental health disorders (MHDs) (P < 0.001) and autoimmune disease multimorbidity (AIDm) (P < 0.001).In regression analysis, the presence of AIDm [odds ratio (OR) = 1.4; 95% CI: 1.1, 1.7; P = 0.003), or a MHD (OR = 1.7; 95% CI: 1.1, 2.6; P = 0.007), or being a Moderna vaccine recipient (OR = 1.5; 95% CI: 1.09, 2.2; P = 0.014) were predictors of flares. Use of MMF (OR = 0.5; 95% CI: 0.3, 0.8; P = 0.009) and glucocorticoids (OR = 0.6; 95% CI: 0.5, 0.8; P = 0.003) were protective.A higher frequency of patients with AIRDs reported overall active disease post-vaccination compared with before vaccination (OR = 1.3; 95% CI: 1.1, 1.5; P < 0.001). Conclusion: Flares occur in nearly 1 in 10 individuals with AIRDs after COVID vaccination; people with comorbidities (especially AIDm), MHDs and those receiving the Moderna vaccine are particularly vulnerable. Future avenues include exploring flare profiles and optimizing vaccine strategies for this group.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19
autoimmunity
flares
rheumatic
vaccination
vaccination hesitancy
Megjelenés:
Rheumatology. - 62 : 12 (2023), p. 3838-3848. -
További szerzők:
Naveen, R.
Day, Jessica
Sen, Parikshit
Vaidya, Binit
Nune, Arvind
Nikiphorou, Elena (reumatológus)
Tan, Ai Lyn
Agarwal, Vishwesh
Saha, Sreoshy
Shinjo, Samuel Katsuyuki
Ziade, Nelly
Joshi, Mrudula
Velikova, Tsvetelina
Milchert, Marcin
Parodis, Ioannis
Gracia-Ramos, Abraham Edgar
Cavagna, Lorenzo
Kuwana, Masataka
Knitza, Johannes
Makol, Ashima
Patel, Aarat
Pauling, John D.
Wincup, Chris
Barman, Bhupen
Zamora Tehozol, Erick Adrian
Rojas Serrano, Jorge
García-De La Torre, Ignacio
Colunga-Pedraza, Iris J.
Merayo-Chalico, Javier
Chibuzo, Okwara Celestine
Katchamart, Wanruchada
Akawatcharangura Goo, Phonpen
Shumnalieva, Russka
Chen, Yi-Ming
Hoff, Leonardo Santos
El Kibbi, Lina
Halabi, Hussein
Sazliyana Shaharir, Syahrul
Hasan, A. T. M. Tanveer
Dey, Dzifa
Gutiérrez, Carlos-Enrique Toro
Caballero-Uribe, Carlo Vinicio
Lilleker, James B.
Salim, Babur
Gheita, Tamer A.
Chatterjee, Tulika
Saavedra, Miguel A.
Distler, Oliver
Chinoy, Hector
Agarwal, Vikas
Aggarwal, Rohit
Gupta, Latika
Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
COVAD Study Group
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
7.
001-es BibID:
BIBFORM110887
035-os BibID:
(WoS)000999243100001 (Scopus)85180733005
Első szerző:
Naveen, R.
Cím:
Flares in IIMs and the timeline following COVID-19 vaccination : a combined analysis of the COVAD-1 and 2 surveys / Naveen R., Sen Parikshit, Griger Zoltán, Day Jessica, Joshi Mrudula, Nune Arvind, Nikiphorou Elena, Saha Sreoshy, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Velikova Tsvetelina, Milchert Marcin, Jagtap Kshitij, Parodis Ioannis, Edgar Gracia-Ramos Abraham, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Chen Yi Ming, Makol Ashima, Agarwal Vishwesh, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Zamora Tehozol Erick Adrian, Serrano Jorge Rojas, García-De La Torre Ignacio, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Goo Phonpen Akawatcharangura, Shumnalieva Russka, Hoff Leonardo Santos, Kibbi El Lina, Halabi Hussein, Vaidya Binit, Shaharir Syahrul Sazliyana, Hasan A. T. M. Tanveer, Dey Dzifa, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo Vinicio, Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Distler Oliver, Saavedra Miguel A., COVAD study group, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika
Dátum:
2024
ISSN:
1462-0324 1462-0332
Megjegyzések:
Objectives: Disease flares in the post COVID-19 vaccination period represent a prominent concern, though risk factors are poorly understood. We studied these flares among patients with idiopathic inflammatory myopathies (IIMs) and other autoimmune rheumatic diseases (AIRDs). Methods: The COVAD-1 and -2 global surveys were circulated in early 2021 and 2022 respectively, and we captured demographics, comorbidities, AIRDs details, COVID-19 infection history, and vaccination details.Flares of IIMs were defined as a. patient self-reported, b. immunosuppression (IS) denoted, c. clinical sign directed, and d. with >7.9-point MCID worsening of PROMISPF10a score. Risk factors of flares were analyzed using regression models. Results: Of 15165 total respondents, 1278 IIMs (age 63 years, 70.3% female, 80.8% Caucasians), and 3453 AIRDs were included. Flares of IIM were seen in 9.6%, 12.7%, 8.7%, and 19.6% patients by definitions a-d respectively with a median time to flare of 71.5 (10.7-235) days, similar to AIRDs. Patients with active IIMs pre-vaccination (OR:1.2; 95%CI:1.03-1.6, p = 0.025) were prone to flares, while those receiving Rituximab (OR:0.3; 95%CI:0.1-0.7, p = 0.010) and Azathioprine (OR:0.3, 95%CI:0.1-0.8, p = 0.016) were at lower risk. Female gender and comorbidities predisposed to flares requiring changes in immunosuppression. Asthma (OR: 1.62; 95%CI: 1.05-2.50, p = 0.028) and higher pain VAS (OR: 1.19; 95%CI: 1.11-1.27, p < 0.001) were associated with disparity between self-reported and IS-denoted flares. Conclusion: A diagnosis of IIMs confers an equal risk of flares in the post COVID-19 vaccination period to AIRDs, with active disease, female gender, and comorbidities conferring a higher risk. Disparity between patient and physician reported outcomes represents a future avenue for exploration.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19 Vaccines
Disease Exacerbation
Idiopathic Inflammatory Myopathies
Patient Reported Outcomes
Megjelenés:
Rheumatology. - 63 : 1 (2024), p. 127-139. -
További szerzők:
Sen, Parikshit
Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Day, Jessica
Joshi, Mrudula
Nune, Arvind
Nikiphorou, Elena (reumatológus)
Saha, Sreoshy
Tan, Ai Lyn
Shinjo, Samuel Katsuyuki
Ziade, Nelly
Velikova, Tsvetelina
Milchert, Marcin
Jagtap, Kshitij
Parodis, Ioannis
Gracia-Ramos, Abraham Edgar
Cavagna, Lorenzo
Kuwana, Masataka
Knitza, Johannes
Chen, Yi Ming
Makol, Ashima
Agarwal, Vishwesh
Patel, Aarat
Pauling, John D.
Wincup, Chris
Barman, Bhupen
Zamora Tehozol, Erick Adrian
Serrano, Jorge Rojas
García-De La Torre, Ignacio
Colunga-Pedraza, Iris J.
Merayo-Chalico, Javier
Chibuzo, Okwara Celestine
Katchamart, Wanruchada
Akawatcharangura Goo, Phonpen
Shumnalieva, Russka
Hoff, Leonardo Santos
El Kibbi, Lina
Halabi, Hussein
Vaidya, Binit
Shaharir, Syahrul Sazliyana
Hasan, A. T. M. Tanveer
Dey, Dzifa
Gutiérrez, Carlos-Enrique Toro
Caballero-Uribe, Carlo Vinicio
Lilleker, James B.
Salim, Babur
Gheita, Tamer A.
Chatterjee, Tulika
Distler, Oliver
Saavedra, Miguel A.
Chinoy, Hector
Agarwal, Vikas
Aggarwal, Rohit
Gupta, Latika
Nagy-Vincze Melinda (1985-) (orvos)
COVAD Study Group
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
8.
001-es BibID:
BIBFORM117880
035-os BibID:
(WOS)001116143800001 (Scopus)85181481512
Első szerző:
Panchawagh, Suhrud
Cím:
COVID-19 breakthrough infections in type 1 diabetes mellitus : a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group / Panchawagh Suhrud, Ravichandran Naveen, Barman Bhupen, Nune Arvind, Javaid Mahnoor, Gracia-Ramos Abraham Edgar, Day Jessica, Joshi Mrudula, Kuwana Masataka, Saha Sreoshy, Pande Arunkumar R., Caballero-Uribe Carlo Vinicio, Velikova Tsvetelina, Parodis Ioannis, Knitza Johannes, Kadam Esha, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Boro Hiya, COVAD Study Group, Aggarwal Rohit, Agarwal Vikas, Chatterjee Tulika, Gupta Latika
Dátum:
2023
ISSN:
0172-8172 1437-160X
Megjegyzések:
To investigate the frequency, profile, and severity of COVID-19 breakthrough infections (BI) in patients with type I diabetes mellitus (T1DM) compared to healthy controls (HC) after vaccination. The second COVID-19 Vaccination in Autoimmune Diseases (COVAD-2) survey is a multinational cross-sectional electronic survey which has collected data on patients suffering from various autoimmune diseases including T1DM. We performed a subgroup analysis on this cohort to investigate COVID-19 BI characteristics in patients with T1DM. Logistic regression with propensity score matching analysis was performed. A total of 9595 individuals were included in the analysis, with 100 patients having T1DM. Among the fully vaccinated cohort, 16 (16%) T1DM patients had one BI and 2 (2%) had two BIs. No morbidities or deaths were reported, except for one patient who required hospitalization with oxygen without admission to intensive care. The frequency, clinical features, and severity of BIs were not significantly different between T1DM patients and HCs after adjustment for confounding factors. Our study did not show any statistically significant differences in the frequency, symptoms, duration, or critical care requirements between T1DM and HCs after COVID-19 vaccination. Further research is needed to identify factors associated with inadequate vaccine response in patients with BIs, especially in patients with autoimmune diseases.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Breakthrough infections
COVID-19
Survey
Type 1 diabetes mellitus
Vaccine
Megjelenés:
Rheumatology International. - 44 : 1 (2023), p. 73-80. -
További szerzők:
Ravichandran, Naveen
Barman, Bhupen
Nune, Arvind
Javaid, Mahnoor
Gracia-Ramos, Abraham Edgar
Day, Jessica
Joshi, Mrudula
Kuwana, Masataka
Saha, Sreoshy
Pande, Arunkumar R.
Caballero-Uribe, Carlo Vinicio
Velikova, Tsvetelina
Parodis, Ioannis
Knitza, Johannes
Kadam, Esha
Tan, Ai Lyn
Shinjo, Samuel Katsuyuki
Boro, Hiya
Aggarwal, Rohit
Agarwal, Vikas
Chatterjee, Tulika
Gupta, Latika
Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Nagy-Vincze Melinda (1985-) (orvos)
COVAD Study Group
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
9.
001-es BibID:
BIBFORM123985
035-os BibID:
(scopus)85193061304 (wos)001221758000001
Első szerző:
Shumnalieva, Russka
Cím:
Characteristics of emerging new autoimmune diseases after COVID-19 vaccination : A sub-study by the COVAD group / Shumnalieva Russka, Ravichandran Naveen, Hannah Jennifer, Javaid Mahnoor, Darooka Naitica, Roy Debaditya, Gonzalez Daniel E., Velikova Tsvetelina, Milchert Marcin, Kuwana Masataka, Joshi Mrudula, Gracia-Ramos Abraham Edgar, Boyd Peter, Yaadav Praggya, Cheng Karen, Kobert Linda, Cavagna Lorenzo, Sen Parikshit, Day Jessica, Makol Ashima, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo V., Saha Sreoshy, Parodis Ioannis, Dey Dzifa, Nikiphorou Elena, Distler Oliver, Kadam Esha, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Knitza Johannes, Chinoy Hector, Aggarwal Rohit, Agarwal Vikas, Gupta Latika, COVAD Study Group
Dátum:
2024
ISSN:
1756-1841
Megjegyzések:
Background Despite the overall safety and efficacy of COVID-19 vaccinations, rare cases of systemic autoimmune diseases (SAIDs) have been reported post-vaccination. This study used a global survey to analyze SAIDs in susceptible individuals' post-vaccination. Methods A cross-sectional study was conducted among participants with self-reported new-onset SAIDs using the COVID-19 Vaccination in Autoimmune Diseases (COVAD) 2 study dataset?a validated, patient-reported e-survey?to analyze the long-term safety of COVID-19 vaccines. Baseline characteristics of patients with new-onset SAIDs and vaccinated healthy controls (HCs) were compared after propensity score matching based on age and sex in a 1:4 ratio. Results Of 16?750 individuals, 74 (median age 52?years, 79.9% females, and 76.7% Caucasians) had new-onset SAID post-vaccination, mainly idiopathic inflammatory myopathies (IIMs) (n?=?23, 31.51%), arthritis (n?=?15; 20.53%), and polymyalgia rheumatica (PMR) (n?=?12, 16.40%). Higher odds of new-onset SAIDs were noted among Caucasians (OR?=?5.3; 95% CI?=?2.9?9.7; p?<?.001) and Moderna vaccine recipients (OR?=?2.7; 95% CI?=?1.3?5.3; p?=?.004). New-onset SAIDs were associated with AID multimorbidity (OR?=?1.4; 95% CI?=?1.1?1.7; p?<?.001), mental health disorders (OR?=?1.6; 95% CI?=?1.3?1.9; p?<?.001), and mixed race (OR?=?2.2; 95% CI?=?1.2?4.2; p?=?.010), where those aged >60?years (OR?=?0.6; 95% CI?=?0.4?0.8; p?=?.007) and from high/medium human development index (HDI) countries (compared to very high HDI) reported fewer events than HCs. Conclusion This study reports a low occurrence of new-onset SAIDs following COVID-19 vaccination, primarily IIMs, PMR, and inflammatory arthritis. Identified risk factors included pre-existing AID multimorbidity, mental health diseases, and mixed race. Revaccination was well tolerated by most patients; therefore, we recommend continuing COVID-19 vaccination in the general population. However, long-term studies are needed to understand the autoimmune phenomena arising post-vaccination.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:
International Journal of Rheumatic Diseases. - 27 : 5 (2024), p. 1-11. -
További szerzők:
Ravichandran, Naveen
Hannah, Jennifer
Javaid, Mahnoor
Darooka, Naitica
Roy, Debaditya
Gonzalez, Daniel E.
Velikova, Tsvetelina
Milchert, Marcin
Kuwana, Masataka
Joshi, Mrudula
Gracia-Ramos, Abraham Edgar
Boyd, Peter
Yaadav, Praggya
Cheng, Karen
Kobert, Linda
Cavagna, Lorenzo
Sen, Parikshit
Day, Jessica
Makol, Ashima
Gutiérrez, Carlos-Enrique Toro
Caballero-Uribe, Carlo Vinicio
Saha, Sreoshy
Parodis, Ioannis
Dey, Dzifa
Nikiphorou, Elena (reumatológus)
Distler, Oliver
Kadam, Esha
Tan, Ai Lyn
Shinjo, Samuel Katsuyuki
Ziade, Nelly
Knitza, Johannes
Chinoy, Hector
Aggarwal, Rohit
Agarwal, Vikas
Gupta, Latika
Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
COVAD Study Group
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
Rekordok letöltése
1
Corvina könyvtári katalógus v8.2.27
© 2023
Monguz kft.
Minden jog fenntartva.